News articles about Luminex (NASDAQ:LMNX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Luminex earned a news impact score of 0.04 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 45.1244855502657 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several analysts have recently issued reports on LMNX shares. TheStreet upgraded Luminex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 1st. BTIG Research started coverage on Luminex in a research note on Friday, January 5th. They set a “buy” rating and a $24.00 price target for the company. Jefferies Group reiterated a “hold” rating and set a $21.00 price target on shares of Luminex in a research note on Friday, October 20th. Finally, BidaskClub upgraded Luminex from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.50.
Shares of Luminex (NASDAQ:LMNX) opened at $19.31 on Tuesday. Luminex has a 52 week low of $17.68 and a 52 week high of $22.42. The firm has a market capitalization of $886.82, a P/E ratio of 29.26, a P/E/G ratio of 1.92 and a beta of 0.13.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be paid a dividend of $0.06 per share. The ex-dividend date is Thursday, March 22nd. This represents a $0.24 annualized dividend and a yield of 1.24%. Luminex’s payout ratio is 36.36%.
In related news, Director G Walter Loewenbaum II sold 50,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $21.79, for a total transaction of $1,089,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 131,698 shares of company stock valued at $2,761,201. 6.90% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This article was first reported by Stock Observer and is the property of of Stock Observer. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thestockobserver.com/2018/02/06/luminex-lmnx-earns-news-sentiment-score-of-0-04.html.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.